drugset
drugset / Trial / NCT02230306

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

NCT02230306 ↗

Phase 2 Terminated 5 enrolled Melissa Burgess, MD Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness of the combination of vemurafenib with cobimetinib in patients with active melanoma brain metastases.

Timeline

Start
2015-02
Primary completion
2016-03
Completion
2016-03

Outcome

Outcome not reported

Stopped (Enrollment): “closed due to slow accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cobimetinib Small molecule 60 mg —
Subject Vemurafenib Small molecule 960 mg —

Indications

metastatic melanoma